Associations of HLA-DRB and HLA-DQ genes with two and five year outcomes in rheumatoid arthritis

We were interested in the results of the longitudinal study by Eberhardt and colleagues,1 who examined the relationship between HLA-DRB and HLA-DQ genes and outcomes in rheumatoid arthritis. Their results, showing a lack of relationship between HLA-DQ variants and arthritic disease severity, are in keeping with the results of our previous cross-sectional study that showed no influence of HLA-DQ variants on arthritic disease severity, in addition to demonstrating a definite relationship between homozygosity for HLA-DR4 and severity of arthritic disease.2

Eberhardt and coworkers have gone on to look for a relationship between HLA variants and risk of extra-articular disease. Again, in previous studies we have looked at this relationship,3 and showed in cross-sectional studies that different forms of extra-articular rheumatoid disease such as Felty’s syndrome, major vasculitis, and various forms of lung disease have different HLA associations. We consider this an important point to make, as such associations may be lost if different forms of extra-articular rheumatoid disease are analysed together.

The HLA associations in Felty’s syndrome and in major forms of rheumatoid vasculitis have been particularly interesting, in that Felty’s syndrome has shown an association with a particular HLA haplotype (B44-Bf-B-C4A*3-C4B*Q0-DR4-DQB1*0301), while major rheumatoid vasculitis has shown associations with the DRB1*0401 variant of HLA-DR4 and with the C4 null allele, C4A*Q0.4

D M GRENNA
WOLLIER
Department of Rheumatology
Whiston Hospital for Joint Disease
Wigan WN6 9EP, United Kingdom


LETTER TO THE EDITOR

Rheumatoid arthritis preceding the onset of polyarticular tophaceous gout

Rheumatoid arthritis (RA) and gout are relatively common diseases, but their coexistence is extremely rare. The diagnosis of RA and gout is hampered because 10% of patients with RA have hyperuricaemia1 and 30% of patients with tophaceous gout may have rheumatoid arthritis.2-4 It is necessary, therefore, to meet the terms of strict criteria before concluding that a patient has both diseases. The criteria include: serosporous erosive RA, or histological confirmation of rheumatoid nodules or pannus, and recurrent attacks of gout with identification of monosodium urate (MSU) crystals.

Up to December 1995, 14 cases of coexistent RA and gout as defined above were reported.5-6 We now report another case, review the literature, and discuss possible risk factors for the development of gout in our patient.

A 61 year old white woman with RA of more than 25 years duration presented in December 1994 with a swollen, painful thumb with a whitish, chalk-like discharge. Her past history included obesity and hypertension treated with hydrochlorothiazide. RA had been diagnosed based on the presence of polyarthritis in a rheumatoid distribution, and treated with different second line agents over time; at presentation she was receiving oral gold and prednisone 7.5 mg/day.

Laboratory data from 1983 revealed a serum uric acid concentration of 132 mg/l and a positive RF (titre 2560). In 1984, rheumatoid nodules over the olecranon bursa, ulnar deviation of both wrists, and swan neck deformities were observed. Fluid from both knees contained 70 000/mm³ leucocytes, with predominance of polymorphonuclear cells; MSU crystals were not found.

In November 1992, the patient had acute right ankle swelling; septic arthritis was suspected. Ankle radiographs showed changes compatible with chronic RA, and magnetic resonance showed a subtalar effusion, but an arthrocentesis was unsuccessful. Serum uric acid concentration was again increased (132 mg/l); blood cultures were negative. Her condition improved spontaneously and continued about the same until August 1994, when she noted multiple subcutaneous nodules (2–3 mm in diameter) over the extensor surfaces of her upper and lower extremities. MSU crystals were demonstrated in the material drained from her thumb. Serum uric acid concentration was 118 mg/l and RF was negative. Radiographs of hands and feet revealed findings of RA and gout: collapse of both wrists, marked subluxations of the metacarpophalangeal joints bilaterally, large erosions of the distal phalanges of the thumb, and an erosion on the lateral aspect of the fifth metatarsal head with calcified intraosseous tophi (figure).

The coexistence of gout and RA in our patient is unquestionable. She had evidence of serosorptive destructive RA, hyperuricaemia, acute gout, and MSU crystals. Coexistent radiographic changes of RA and gout have been described previously.7 As RA is far more prevalent than gout, it would be expected that a patient with both disorders would be diagnosed first as having RA. However, in 10 of the 14 previously reported cases (among whom the ratio of men to women was 2:5:1) the first diagnosis was gout (table).

The reason for the usual mutual exclusion of RA and gout is not clear. Hyperuricaemia may have some ‘protective immunosuppressive effect’ on RA,8-9 and Fc receptors adsorbed on MSU crystal surfaces10 and a negative correlation between serum uric acid concentration and clinical activity in RA have been demonstrated.7 As noted, hyperuricaemia occurs in about 10% of RA patients,11 and has been related to the use of aspirin and analgesics, which may affect the excretion or renal handling of uric acid. Most rheumatic diseases disproportionately affect women rather than men; however, while women are distinctly less affected by gout in premenopausal years, their frequency of gout increases afterwards.12 Predisposing factors for gout include an underlying joint disease,13-15 use of diuretics, and renal impairment.16 Gout in women is commonly polyarticular,2,17 tophi
appear sooner than in men, and inter-phalangeal joints are involved frequently.

Although the coexistence of RA and gout is extremely rare, the latter should be sought in patients with inflammatory arthropathies and otherwise asymptomatic hyperuricemia if acute or chronic gout, or both, are to receive the correct treatment in these patients.

ABRAHAM ZONANA-NACACH
GRACIELA S ALARCON
Division of Clinical Immunology and Rheumatology,
The University of Alabama at Birmingham,
Birmingham, Alabama, USA

WILLIAM W DANIEL
Department of Radiology,
The University of Iowa,
Iowa City, Iowa, USA

Correspondence to: Dr Graciela S Alarcón,
University Station, MEB 615/1813 6th Avenue
South, Birmingham, AL 35294, USA

This work was partially supported by the Instituto Mexicano del Seguro Social (IMSS) (A-Z-N) and the National Institute of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Center grant P-60-AR-20614 (G SA).

We are grateful to Ms Ella Henderson for preparation of the manuscript.


Correction
Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?


It is regretted that an incorrect affiliation was given for Dr H J Dinant, who is now rheumatologist at the Jan van Breemen Instituut, Amsterdam.